The impact of AMIGO2 on prognosis and hepatic metastasis in gastric cancer patients

Abstract Background Gastric cancer (GC) is one of the most common malignancies, and the liver is the most common site of hematogenous metastasis of GC. AMIGO2 is a type I transmembrane protein that has been implicated in tumour cell adhesion in adenocarcinomas; however, its importance in GC remains...

Full description

Bibliographic Details
Main Authors: Keisuke Goto, Masaki Morimoto, Mitsuhiko Osaki, Akimitsu Tanio, Runa Izutsu, Yoshiyuki Fujiwara, Futoshi Okada
Format: Article
Language:English
Published: BMC 2022-03-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-022-09339-0
Description
Summary:Abstract Background Gastric cancer (GC) is one of the most common malignancies, and the liver is the most common site of hematogenous metastasis of GC. AMIGO2 is a type I transmembrane protein that has been implicated in tumour cell adhesion in adenocarcinomas; however, its importance in GC remains undetermined. Methods We analyzed AMIGO2 expression by immunohistochemistry using the specific monoclonal antibody for human AMIGO2 in 128 patients who underwent GC surgery to evaluate its relationship between various metastatic and clinical outcomes in GC. Results Immunohistochemistry revealed that AMIGO2 expression was an independent prognostic factor for overall survival, disease-specific survival, and liver metastasis in GC patients. Conclusions This study showed that AMIGO2 is induced in GC tissues and can mediate hepatic metastasis. Determining AMIGO2 expression in GC will help predict patient prognosis and the incidence of liver metastasis.
ISSN:1471-2407